Surface Oncology Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Surface Oncology Inc
Access all reports
Surface Oncology Inc is a clinical-stage immuno-oncology company dedicated to the development of novel antibody therapies for the treatment of cancer. Its focus lies in creating and advancing treatments designed to modify the tumor microenvironment, thereby supporting and sustaining anti-tumor immune responses. The company's product portfolio includes SRF388, aimed at treating diseases such as renal cell carcinoma, hepatocellular carcinoma, and non-small cell lung cancer, as well as SRF617 for various tumors including gastric cancer, prostate cancer, PD-(L)1 relapsed cancer, and pancreatic cancer. Surface Oncology is also working on SRF114, NZV930, and GSK4381562 antibodies, alongside conducting research and development activities and pre-clinical studies. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
SURF
Country
🇺🇸 United States